MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$376,400K
Proceeds from the
exercise of warrants
$3,655K
Proceeds from the
exercise of stock options
$1,930K
Proceeds from issuance of
common stock under...
$840K
Sales of marketable
securities
$7,144K
Net cash provided by
(used in) investing...
$156,358K
Net cash provided by
(used in) financing...
$6,425K
Effect of exchange rate
changes on cash and cash...
$141K
Canceled cashflow
$227,186K
Net increase
(decrease) in cash and cash...
-$8,342K
Canceled cashflow
$162,924K
Accrued research and
development expenses
$11,207K
Stock-based compensation
expense
$10,555K
In process
research and development...
$7,475K
Accrued expenses
$1,448K
Amortization of long-term
debt discount and...
$985K
Amortization of operating
lease right-of-use...
$978K
Depreciation and
amortization
$24K
Purchase of marketable
securities
$227,107K
Purchase of property and
equipment
$79K
Net cash used in
operating activities
-$171,266K
Canceled cashflow
$32,672K
Net loss
-$170,370K
Prepaid expenses and
other current assets
$8,453K
Amortization of premium on
investments, net of accretion...
$7,278K
Receivable from contracts
with collaborators
$6,889K
Contract liabilities
-$6,326K
Accounts payable
-$2,747K
Operating lease
liabilities
$961K
Accrued compensation
and benefits
-$784K
Other assets
$125K
Net realized gain on
investments
$5K
Back
Back
Cash Flow
source: myfinsight.com
Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. (GOSS)